Baghdad – WAA
The General Company for Marketing Medicines and Medical Supplies (Kimadia) confirmed today, Friday, the completion of all cancer drug contracts for the year 2024, and while it indicated that the percentage of drug supply reached 95 percent, it confirmed that they are available in all health centers.
The company’s senior pharmacist, Mustafa Saadi, told the (INA): “The issue of providing cancer drugs this year has achieved a great accomplishment, as the drug supply rates have so far reached more than 95 percent of the rates we are supposed to provide,” noting that “this percentage can be supplied in the first quarter of 2025.”
He added, “The 2024 contracts have been fully completed, and the drug shipments are arriving in stages,” noting that “the company’s general warehouses and the rest of the institutions have a certain capacity, as it is safer for the drugs to come in the form of shipments, and it has reached 95 percent or more so far, which has provided our health institutions with the appropriate quantities.”
He stressed that “since its inception, the government has been keen to provide all the necessary requirements to provide these medicines by contracting with reputable companies and companies that have previously been dealt with under the direct supervision of the Prime Minister, the Minister of Health, and the General Company for Marketing Medicines and Medical Supplies, and with continuous work.”
He stressed that “cancer drugs are expensive and are urgently and importantly required to be available in institutions because the average Iraqi citizen cannot afford to buy them from outside health institutions,” explaining that “the subject of the drug must be safe, and it must be evaluated and examined.”
Last Wednesday, Health Minister Saleh Al-Hasnawi announced the completion of 95 percent of cancer drug contracts for the year 2024 before the end of the year, which reflects the extent of health efforts and follow-up.